Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma

Abstract

Efficacy of HAART was independently associated with prolonged survival in this large cohort of patients with ARL. Information on patient's response to HAART is crucial for the evaluation of future treatment strategies.

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

“…Some studies have reported that patients with Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) who started cART at the same time as chemotherapy showed increased survival [54][55][56], reduced toxicity (especially bone marrow toxicity), and a decreased risk of developing opportunistic infections. Therefore, cART should be started before or at the same time as chemotherapy in patients diagnosed with HL, NHL, or Kaposis's sarcoma (A-I).…”

Linfoma relacionado a infección por virus de la inmunodeficiencia humana en un hospital público de Santiago, Chile

“…Sin embargo, se ha observado un incremento de neoplasias no asociadas a síndrome de inmunodefi ciencia adquirida (SIDA) como el linfoma de Hodgkin (LH), cáncer anal, pulmón, cabeza y cuello y conjuntiva [1][2][3] . El uso de TARV ha mejorado el pronóstico de pacientes con linfoma debido a la reconstitución inmunológica [4][5][6][7][8] , aunque la sobrevida es signifi cativamente menor que en pacientes seronegativos, debido a una menor tolerancia a drogas inmunosupresoras, mayor posibilidad de efectos adversos y mayor riesgo de infecciones 1,9,10 . El objetivo de este estudio fue analizar las características clínicas, tratamiento, sobrevida y factores pronósticos, de pacientes seropositivos con linfoma, diagnosticados y tratados en el Hospital del Salvador, centro de referencia del Area Oriente de la Región Metropolitana de Santiago, I, II y III regiones del país, donde se controlan alrededor de 1.500 pacientes con TARV.…”

Ten‐year survival among HIV‐1‐infected subjects with AIDS or non‐AIDS‐defining malignancies

“…10 These findings may be attributable both to specific cancer characteristics in HIV-infected individuals (a more aggressive behavior and an advanced stage at diagnosis) [6][7][8]11,12 and to subject characteristics (immunodeficiency, low performance status). The use of HAART improved short-and medium-term survival in HIV-infected patients with cancer, 8 especially those with ADM [13][14][15] and some types of NADM (e.g., HD) 16,17 and reduced the difference from the general population. 8 However, very few studies described 10-year survival in patients with HIV and cancer, and the only published data are limited to subjects with NHL, Kaposi's sarcoma (KS), and anal cancer.…”